정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 618 | Active, not recruiting | Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) | COVID-19 Immunisation | Biological: mRNA-1273 | Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID), ModernaTX, Inc. | NIH | 120 | All | 18 Years ~ 99 Years | Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States |
| 617 | Active, not recruiting | Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 | SARS-CoV-2 Infection | Biological: 20-valent pneumococcal conjugate vaccine (20vPnC) Biological: BNT162b2 Other: Saline |
Phase 3 | Pfizer | INDUSTRY | 582 | All | 65 Years | Anaheim Clinical Trials, LLC, Anaheim, California, United States Diablo Clinical Research, Inc., Walnut Creek, California, United States Alliance for Multispecialty Research, LLC, Coral Gables, Florida, United States Indago Research & Health Center, Inc, Hialeah, Florida, United States Research Centers of America ( Hollywood ), Hollywood, Florida, United States Acevedo Clinical Research Associates, Miami, Florida, United States Clinical Neuroscience Solutions, Orlando, Florida, United States Clinical Research Atlanta, Stockbridge, Georgia, United States East-West Medical Research Institute, Honolulu, Hawaii, United States Solaris Clinical Research, Meridian, Idaho, United States Alliance for Multispecialty Research, LLC, Newton, Kansas, United States Clinical Research Professionals, Chesterfield, Missouri, United States Sundance Clinical Research, Saint Louis, Missouri, United States Meridian Clinical Research, LLC, Omaha, Nebraska, United States Meridian Clinical Research, LLC, Endwell, New York, United States Accellacare - Wilmington, Wilmington, North Carolina, United States Aventiv Research Inc, Columbus, Ohio, United States Alliance for Multispecialty Research - Weisgarber Medical Park, Knoxville, Tennessee, United States Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Memphis, Tennessee, United States Benchmark Research, Austin, Texas, United States Diagnostics Research Group, San Antonio, Texas, United States DM Clinical Research, Tomball, Texas, United States Martin Diagnostic Clinic, Tomball, Texas, United States J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States Wenatchee Valley Hospital, Wenatchee, Washington, United States |
| 616 | Active, not recruiting | Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naive and Previously Vaccinated Adults | COVID-19 Immunisation | Biological: mRNA-1273 Biological: mRNA-1273.351 |
Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID), ModernaTX, Inc. | NIH | 135 | All | 18 Years ~ 99 Years | Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville, Tennessee, United States Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States |
| 615 | Active, not recruiting | Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers | COVID-19 | Biological: AdCLD-CoV19 | Phase 2 | Cellid Co., Ltd. | INDUSTRY | 150 | All | 19 Years ~ 64 Years | Korea University Ansan Hospital, Ansan, Province, Korea, Republic of The Catholic University of Korea, ST. Vincent's Hospital, Suwon, Province, Korea, Republic of Hallym University Kangnam Sacred Heart Hospital, Seoul, State, Korea, Republic of The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, State, Korea, Republic of Korea University Guro Hospital, Seoul, Korea, Republic of |
| 614 | Recruiting | Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers | Covid19 | Biological: AdCLD-CoV19-1 | Phase 1 | Cellid Co., Ltd. | INDUSTRY | 40 | All | 19 Years ~ 64 Years | Korea University Ansan Hospital, Ansan, Province, Korea, Republic of The Catholic University of Korea, ST. Vincent's Hospital, Suwon, Province, Korea, Republic of Korea University Guro Hospital, Seoul, State, Korea, Republic of |
| 613 | Recruiting | Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 | COVID-19 | Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Biological: Placebo on a 0- and 28-day schedule Biological: Placebo on a 0- and 14-day schedule |
Phase 2 | Chinese Academy of Medical Sciences, West China Second University Hospital, Yunnan Center for Disease Control and Prevention | OTHER | 942 | All | 18 Years ~ 59 Years | West China Second University Hospital, Sichuan University / West China women's and children's Hospital, Chengdu, Sichuan, China |
| 612 | Enrolling by invitation | Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ?60 Years | COVID-19 | Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Biological: Placebo on a 0- and 28-day schedule |
Phase 2 | Chinese Academy of Medical Sciences, West China Second University Hospital, Yunnan Center for Disease Control and Prevention | OTHER | 471 | All | 60 Years | West China Second University Hospital, Sichuan University / West China women's and children's Hospital, Chengdu, Sichuan, China |
